Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emerson Y Chen

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Diseases of the Colon and Rectum|July 26, 2023
Expert Commentary on Microsatellite Instability in Colorectal Cancer: The Evolving Role of ImmunotherapyEmerson Y Chen
Clinics in Colon and Rectal Surgery|September 7, 2018
Small Bowel AdenocarcinomaEmerson Y Chen, Gina M Vaccaro
JAMA Internal Medicine|April 28, 2020
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019Emerson Y Chen, Alyson Haslam, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|November 7, 2020
Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharingKate Rosen, Vinay Prasad, Emerson Y Chen
JAMA Internal Medicine|May 29, 2019
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response RateEmerson Y Chen, Vikram Raghunathan, Vinay Prasad
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and Misconceptions-ReplyJohn Marquart, Emerson Y Chen, Vinay Prasad
JAMA Oncology|May 1, 2018
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologyJohn Marquart, Emerson Y Chen, Vinay Prasad
Gynecologic Oncology Reports|June 20, 2022
Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testingAnn M Cathcart, Emerson Y Chen, Amanda Bruegl
Journal of Cancer Policy|September 26, 2022
Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysisVinay Prasad, Timothée Olivier, Emerson Y Chen, et al.
JAMA Internal Medicine|April 2, 2019
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical TrialsEmerson Y Chen, Sunil K Joshi, Audrey Tran, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Diseases of the Colon and Rectum|July 26, 2023
Expert Commentary on Microsatellite Instability in Colorectal Cancer: The Evolving Role of ImmunotherapyEmerson Y Chen
Clinics in Colon and Rectal Surgery|September 7, 2018
Small Bowel AdenocarcinomaEmerson Y Chen, Gina M Vaccaro
JAMA Internal Medicine|April 28, 2020
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019Emerson Y Chen, Alyson Haslam, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|November 7, 2020
Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharingKate Rosen, Vinay Prasad, Emerson Y Chen
JAMA Internal Medicine|May 29, 2019
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response RateEmerson Y Chen, Vikram Raghunathan, Vinay Prasad
JAMA Oncology|November 13, 2018
Moving Precision Oncology Forward Amid Myths and Misconceptions-ReplyJohn Marquart, Emerson Y Chen, Vinay Prasad
JAMA Oncology|May 1, 2018
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologyJohn Marquart, Emerson Y Chen, Vinay Prasad
Gynecologic Oncology Reports|June 20, 2022
Patient benefit rate and guarantee time bias in analysis of outcomes for gynecologic oncology patients receiving targeted treatment after somatic tumor genetic testingAnn M Cathcart, Emerson Y Chen, Amanda Bruegl
Journal of Cancer Policy|September 26, 2022
Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysisVinay Prasad, Timothée Olivier, Emerson Y Chen, et al.
JAMA Internal Medicine|April 2, 2019
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical TrialsEmerson Y Chen, Sunil K Joshi, Audrey Tran, et al.
Pageof 6